However, recent evidence suggests that anti-VEGF treatment is also very effective, especially in Zone 1 disease.11, 14 In the BEAT-ROP study, bevacizumab was more successful than LPC in zone 1 disease.6 Here, VEGFA is linked to retinopathy of prematurity.